26th Jan 2015 09:04
LONDON (Alliance News) - Biofrontera AG on Monday said it has completed nearly all the preparations required ahead of the launch of its Ameluz skin cancer drug in Belgium.
The biopharmaceutical company said pricing for the Belgian market has now been agreed and it anticipates making the first sales of the drug in the first quarter.
Biofrontera said Ameluz will benefit from being fully-reimbursed by the Belgian health care system and noted an add-on payment, which is required in Germany, is not required in Belgium.
Bipharma NV will handle the distribution of the drug in Belgium, having already been handed the distribution contract for the Netherlands.
"Ameluz has been well received in Belgium, receiving recognition of the high efficacy and economic viability of the therapy with Ameluz for actinic keratosis, also in comparison to competing products. This will not only give us a head-start in Belgium but should also serve as a positive signal towards other markets in Europe," said Biofrontera Chief Executive Officer Hermann Lübbert.
Shares in Biofrontera were untraded on Monday morning, having last traded at 215.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L